These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12505833)

  • 1. omega-3 Fatty acid for schizophrenia.
    Horrobin DF
    Am J Psychiatry; 2003 Jan; 160(1):188-9; author reply 189. PubMed ID: 12505833
    [No Abstract]   [Full Text] [Related]  

  • 2. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
    Fenton WS; Dickerson F; Boronow J; Hibbeln JR; Knable M
    Am J Psychiatry; 2001 Dec; 158(12):2071-4. PubMed ID: 11729030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schizophrenic symptoms and dietary intake of n-3 fatty acids.
    Mellor JE; Laugharne JD; Peet M
    Schizophr Res; 1995 Dec; 18(1):85-6. PubMed ID: 8929766
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial.
    Emsley R; Niehaus DJ; Oosthuizen PP; Koen L; Ascott-Evans B; Chiliza B; van Rensburg SJ; Smit RM
    Psychiatry Res; 2008 Dec; 161(3):284-91. PubMed ID: 18962989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognitive effects of an omega-3 fatty acid and vitamins E+C in schizophrenia: A randomised controlled trial.
    Bentsen H; Landrø NI
    Prostaglandins Leukot Essent Fatty Acids; 2018 Sep; 136():57-66. PubMed ID: 29079039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The Alpha Omega study].
    Trimarco B; Tavazzi L; Marchioli R
    G Ital Cardiol (Rome); 2011; 12(7-8):469-73. PubMed ID: 21779112
    [No Abstract]   [Full Text] [Related]  

  • 7. A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects.
    Chen AT; Chibnall JT; Nasrallah HA
    Ann Clin Psychiatry; 2015 Nov; 27(4):289-96. PubMed ID: 26554370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Psychosis prevention: expectations met].
    Bechdolf A; Peukert R
    Psychiatr Prax; 2011 Feb; 38(2):58-60. PubMed ID: 21394689
    [No Abstract]   [Full Text] [Related]  

  • 9. Sulpiride augmentation for schizophrenia.
    Wang J; Omori IM; Fenton M; Soares B
    Schizophr Bull; 2010 Mar; 36(2):229-30. PubMed ID: 20061345
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia.
    Emsley R; Chiliza B; Asmal L; du Plessis S; Phahladira L; van Niekerk E; van Rensburg SJ; Harvey BH
    Schizophr Res; 2014 Sep; 158(1-3):230-5. PubMed ID: 24996507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Omega-3 in the treatment of violent schizophrenia patients.
    Qiao Y; Mei Y; Han H; Liu F; Yang XM; Shao Y; Xie B; Long B
    Schizophr Res; 2018 May; 195():283-285. PubMed ID: 28830741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary polyunsaturated fatty acid supplementation, pre-dementia syndromes, and Alzheimer's disease.
    Panza F; Capurso C; D'Introno A; Colacicco AM; Chirico M; Capurso A; Solfrizzi V
    J Am Geriatr Soc; 2007 Mar; 55(3):469-70. PubMed ID: 17341255
    [No Abstract]   [Full Text] [Related]  

  • 13. Methodological concerns in a trial of ziprasidone and olanzapine.
    Carnahan RM; Perry PJ
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
    [No Abstract]   [Full Text] [Related]  

  • 14. [Fish oil for the psyche?].
    Praxis (Bern 1994); 2004 Apr; 93(15):635. PubMed ID: 15108852
    [No Abstract]   [Full Text] [Related]  

  • 15. The costs of drugs for schizophrenia.
    Freedman R; Carpenter WT; Davis JM; Goldman HH; Tamminga CA; Thomas M
    Am J Psychiatry; 2006 Dec; 163(12):2029-31. PubMed ID: 17151146
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparing symptom response among antipsychotic medications in CATIE.
    Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
    J Clin Psychopharmacol; 2013 Feb; 33(1):123-6. PubMed ID: 23288232
    [No Abstract]   [Full Text] [Related]  

  • 17. Limitations of controlled augmentation trials in schizophrenia.
    Stern RG; Schmeidler J; Davidson M
    Biol Psychiatry; 1997 Jul; 42(2):138-43. PubMed ID: 9209731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies.
    Fusar-Poli P; Berger G
    J Clin Psychopharmacol; 2012 Apr; 32(2):179-85. PubMed ID: 22367656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of treatment resistant schizophrenia unresponsive to clozapine.
    Barnes TR; McEvedy CJ; Nelson HE
    Br J Psychiatry Suppl; 1996 Dec; (31):31-40. PubMed ID: 8968653
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antipsychotic polypharmacy in high-utilising patients with schizophrenia].
    Schmidt-Kraepelin C; Puschner B; Loos S; Janssen B
    Psychiatr Prax; 2013 Oct; 40(7):380-4. PubMed ID: 23681790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.